Abstract
The issue of prescribing anticonvulsant drugs during lactation is clinically important, but also complex. Data for some drugs are completely lacking and for other drugs information is only available from single dose or short term studies or case reports. Moreover, limited knowledge exists about the practical impact of the drug concentrations found in breast milk and there are great methodological problems in the assessment of possible adverse drug reactions in infants. Nevertheless, based on current knowledge, some recommendations can be suggested.
Treatment with carbamazepine, valproic acid (sodium valproate) and phenytoin is considered compatible with breastfeeding. Treatment with ethosuximide or phenobarbital (phenobarbitone)/primidone should most probably be regarded as potentially unsafe and close clinical monitoring of the infant is recommended if it is decided to continue breastfeeding. Occasional or short term treatment with benzodiazepines could be considered as compatible with breastfeeding, although maternal diazepam treatment has caused sedation in suckling infants after short term use. During long term use of benzodiazepines, infants should be observed for signs of sedation and poor suckling. Only very limited clinical data are available for the new generation anticonvulsant drugs and no clearcut recommendations can be made until further data are present. If it is decided to continue breast feeding during treatment with these drugs, the infant should be monitored for possible adverse effects.
In general, the drug should be given in the lowest effective dose, guided by maternal serum or plasma drug concentration monitoring. If breast feeding is avoided at times of peak drug levels in milk, the exposure of the infant can be reduced to some extent. As breast milk has considerable advantages over formula milk, the benefits of continuing breast feeding should always be taken into consideration in the risk-benefit analysis.
Similar content being viewed by others
References
Dewey KG, Heinig MJ, Nommsen-Rivers LA. Differences in morbidity between breast-fed and formula-fed infants. J Pediatr 1995; 126: 696–702
Ford K, Labbok M. Breast-feeding and child health in the United States. J Biosoc Sci 1993; 25: 187–94
Wright AL, Holberg CJ, Martinez FD, et al. Breast-feeding and lower respiratory tract illness in the first year of life. BMJ 1989; 299: 946–9
Pisacane A, Graziano L, Mazzarella G, et al. Breast-feeding and urinary tract infection. J Pediatr 1992; 120: 87–9
Saarinen UM, Kajosaari M, Backman A, et al. Prolonged breastfeeding as prophylaxis for atopic disease. Lancet 1979; II: 163–8
Hahn-Zoric M, Fulconis F, Minoli I, et al. Antibody responses to parenteral and oral vaccines are impaired by conventional and low protein formulas as compared to breast-feeding. Acta Paediatr Scand 1990; 79: 1137–42
Byers T, Graham S, Rzepka T, et al. Lactation and breast cancer: evidence for a negative association in premenopausal women. Am J Epidemiol 1985; 121: 664–74
Borgeoise BF. Antiepileptic drug, learning and behavior in childhood epilepsy. Epilepsia 1998; 39: 913–21
Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525–38
Bertilsson L. Geographic/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 1995; 29: 192–209
Casey C, Hambridge KM. Nutritional aspects of human lactation. In: Neville MC, Neifert MR, editors. Lactation. physiology, nutrition and breast-feeding. New York: Plenum Press, 1983: 199–248
Öhman R, Hägg S, Carleborg L, et al. Excretion of paroxetine in breast milk. J Clin Psychiatry 1999; 60: 519–23
Prentice A, Prentice AM, Whitehead RG. Breast-milk fat concentrations of rural African women. Short-term variations within individuals. Br J Nutr 1981: 45: 483–94
Bennett PN. Drugs and human lactation. 2nd ed. Amsterdam: Elsevier, 1996
Wilson JT, Brown DJ, Hinson JL, et al. Pharmacokinetic pitfalls in the estimation of the breast milk/plasma ratio for drugs. Ann Rev Pharmacol Toxicol 1985; 25: 667–89
Anderson PO. Drugs and breast-feeding. Semin Perinatol 1979; 3: 271–8
Morselli PL. Clinical pharmacokinetics in neonates. Clin Pharmacokinet 1976; 1: 81–9
Morselli PL, Franco-Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants. Clin Pharmacokinet 1980; 5: 485–527
Hardman JG, Limbird LE, editors. Goodman & Gilman’s The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1712–92
Andre M, Vert P. Anticonvulsants in the newborn infant. In: Yaffe SJ, Aranda JV, editors. Pediatric pharmacology. 2nd ed. Philadelphia: W.B. Saunders, 1992: 183–92
Scheyer RD, Cramer JA. Pharmacokinetics of antiepileptic drugs. Semin Neurol 1990; 10: 414–21
Bülau P, Paar WD, von Unruh GE. Pharmacokinetics of oxcarbazepine and 10-hydroxy-oxcarbazepine in the newborn child of an oxcarbazepine-treated mother. Eur J Clin Pharmacol 1988; 34: 311–3
Gourley GR, Arend RA. β-glucuronidase and hyperbilirubinaemia in breast-fed and formula-fed babies. Lancet 1986; I: 644–6
Blumer JL, Reed MD. Principles of neonatal pharmacology. In: Yaffe SJ, Aranda JV, editors. Pediatric pharmacology. 2nd ed. Philadelphia: W. B. Saunders, 1992: 164–77
Kuhnz W, Jäger-Roman E, Rating D, et al. Carbamazepine and carbamazepine-10, 11-epoxide during pregnancy and postnatal period in epileptic mothers and their nursed infants. Pharmacokinetics and clinical effects. Pediatr Pharmacol 1983; 3: 199–208
Froescher W, Eichelbaum M, Niesen M, et al. Carbamazepine levels in breast milk. Ther Drug Monitor 1984; 6: 266–71
Pynnönen S, Kanto J, Sillanpää M, et al. Carbamazepine: placental transport, tissue concentrations in foetus and newborn, and level in milk. Acta Pharmacol Toxicol 1977; 41: 244–53
Pynnönen S, Sillanpää M. Carbamazepine and mother’s milk. Lancet 1975; II: 563
Niebyl JR, Blake DA, Freeman JM, et al. Carbamazepine levels in pregnancy and lactation. Obstet Gynecol 1979; 53: 139–40
Kaneko S, Sato T, Suzuki K. The levels of anticonvulsants in breast milk. Br J Clin Pharmacol 1979; 7: 624–7
Kaneko S, Suzuki K, Sato T, et al. The problems of antiepileptic medication in the neonatal period: is breast feeding advisable? In: Janz D, Bossi L, Dam M, et al., editor. Epilepsy, pregnancy and the child. New York: Raven Press, 1981: 343–8
Kok THH, Taitz LS, Bennet MJ, et al. Drowsiness due to clemastine transmitted in breastmilk. Lancet 1982; I: 914–5
Brent NB, Wisner KL. Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. Clin Pediatr (Phila) 1998; 37: 41–4
Wisner KL, Perel JM. Serum levels of valproate and carbamazepine in breastfeeding mother-infant pairs. J Clin Psychopharmacol 1998; 18: 167–9
Koup JR, Rose JQ, Cohen ME. Ethosuximide pharmacokinetics in a pregnant patient and her newborn. Epilepsia 1978; 19: 535–9
Rane A, Tunell R. Ethosuximide in human milk and in plasma of a mother and her nursed infant. Br J Clin Pharmacol 1981; 12: 855–8
Kuhnz W, Koch S, Jakob S, et al. Ethosuximide in epileptic women during pregnancy and lactation period. Placental transfer, serum concentrations in nursed infants and clinical status. Br J Clin Pharmacol 1984; 18: 671–7
Söderman P, Rane A. Ethosuximide and nursing [abstract no. 513]. 3rd World conference on Clinical Pharmacology and Therapeutics; 1986 Jul 27-Aug 1; Stockholm, 182
Kuhnz W, Koch S, Helge H, et al. Primidone and phenobarbital during lactation period in epileptic women: total and free drug serumlevels in the nursed infants and their effects on neonatal behavior. Dev Pharmacol Ther 1988; 11: 147–54
Westerink D, Glerum JH. Separation and microdetermination of phenobarbital and phenytoin in human milk [in Dutch]. Pharm Weekbl 1965; 100: 577–83
Nau H, Jesdinsky D, Wittfoht W. Microassay for primidone and its metabolites phenylethylmalondiamide, phenobarbital and p-hydroxyphenobarbital in human serum, saliva, breast milk and tissues by gas chromatography-mass spectrometry using selected ion monitoring. J Chromatogr 1980; 182: 71–9
Söderman P, Elwin C-E, Liden A. Excretion in milk and blood levels of primidone and phenobarbital in mother and child during primidone treatment [abstract no. 519]. 3rdWorld conference on Clinical Pharmacology and Therapeutics; 1986 Jul 27-Aug 1; Stockholm, 183
Steen B, Rane A, Lönnerholm G, et al. Phenytoin excretion in human breast milk and plasma levels in nursed infants. Ther Drug Monit 1982; 4: 331–4
Rane A, Garle M, Borgå O, et al. Plasma disappearance of transplacentally transferred diphenylhydantoin in the newborn studied by mass fragmentography. Clin Pharmacol Ther 1974; 15: 39–45
Shimoyama R, Ohkubo T, Sugawara K, et al. Monitoring of phenytoin in human breast milk, maternal plasma and cord blood plasma by solid-phase extraction and liquid chromatography. J Pharm Biomed Anal 1998; 17: 863–9
Mirkin BL. Diphenylhydantoin: placental transport, fetal localization, neonatal metabolism, and possible teratogenic effects. J Pediatr 1971; 78: 329–37
Von Unruh GE, Froescher W, Hoffman F, et al. Valproic acid in breast milk. How much is really there? Ther Drug Monit 1984; 6: 272–6
Dickinson R, Harland R, Lynn R, et al. Transmission of valproic acid (Depakene) across the placenta: half life of the drug in mother and baby. J Pediatr 1979; 94: 832–5
Alexander FW. Sodium valproate and pregnancy [letter]. Arch Dis Child 1979; 54: 240
Nau H, Rating S, Koch S, et al. Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother’s milk and clinical status in neonates of epileptic mothers. J Pharmacol Exp Ther 1981; 219: 768–77
Nau H, Helge H, Luck W. Valproic acid in the perinatal period: decreased maternal serum protein binding results in fetal accumulation and neonatal displacement of the drug and some metabolites. J Pediatr 1984; 104: 627–34
Bardy A, Granström ML, Hiilesmaa VK. Valproic acid and breastfeeding. In: Janz D, Bossi L, Dam M, et al., editors. Epilepsy, pregnancy and the child. New York: Raven Press, 1982: 359–60
Philbert A, Pedersen B, Dam M. Concentration of valproate during pregnancy, in the newborn and in breast milk. Acta Neurol Scand 1985; 72: 460–3
Tsuru N, Maeda T, Tsuruoka M. Three cases of delivery under sodium valproate-placental transfer, milk transfer and probable teratogenicity of sodium valproate. Jpn J Psychiatry Neurol 1988; 42: 89–96
Rane A, Bertilsson L, Palmér L. Disposition of placentally transferred carbamazepine in the newborn. Eur J Clin Pharmacol 1975; 8: 283–4
Frey B, Schubiger G, Musy JP. Transient cholestatic hepatitis in a neonate associated with carbamazepine exposure during pregnancy and breast-feeding. Eur J Pediatr 1990; 150: 136–8
Merlob P, Mor N, Litwin A. Transient hepatic dysfunction in an infant of an epileptic mother treated with carbamazepine during pregnancy and breastfeeding. Ann Pharmacother 1992; 26: 1563–5
American Academy of Pediatrics, Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 1994; 93: 137–15
Frensdorf W. Uebergang von Luminal in die Milch. Munch Med Wschr 1926; 73: 322–3
Tyson RM, Schrader EA. Pearlmann HH. Drugs transmitted through breastmilk. J Pediatr 1938; 13: 86–90
Juul S. Barbiturate poisoning via breast milk? [in Danish]. Ugeskr Laeger 1969; 131: 2257–8
Finch E, Lorber J. Methemoglobinemia in the newborn: probably due to phenytoin excreted in milk. J Obstet Gynecol Br Emp 1954; 61: 833–4
Knott C, Reynolds F, Clayden G. Infantile spasms on weaning from breast milk containing anticonvulsants. Lancet 1987; II: 272–3
Brodie MJ. Management of epilepsy during pregnancy and lactation. Lancet 1990; 336: 426–7
Dillon AE, Wagner CL, Wiest D, et al. Drug therapy in the nursing mother. Obstet Gynecol Clin North Am 1997; 24: 675–96
Nau H, Kunz W, Egger HJ, et al. Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics. Clin Pharmacokinet 1982; 7: 508–43
Stahl MMS, Neiderud J, Vinge E. Thrombocytopenic purpura and anemia in a breast-fed infant whose mother was treated with valproic acid. J Pediatr 1997; 130: 1001–3
Goldberg HL. Psychotropic drugs in pregnancy and lactation. Int J Psychiatry Med 1994; 24: 129–47
Söderman P, Matheson I. Clonazepam in breast milk. Eur J Pediatr 1988; 147: 212–3
Fisher JB, Edgren BE, Mammel MC, et al. Neonatal apnea associated with maternal clonazepam therapy: a case report. Obstet Gynecol 1985; 66(3 Suppl.): 34S–5S
Erkkola R, Kanto J. Diazepam and breastfeeding. Lancet 1972; I: 1235–6
Wesson DR, Camber S, Harkey M, et al. Diazepam and desmethyldiazepam in breast milk. J Psychoactive Drugs 1985; 17: 55–6
Brandt R. Passage of diazepam and desmethyldiazepam into breast milk. Arzneimittelforschung 1976; 26: 454–7
Sundsbak HP, Bredesen JE. Diazepam in breast milk [letter in Norwegian]. Tidsskr Nor Laegeforen 1980; 100: 582
Dusci LJ, Good SM, Hall RW, et al. Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam. Br J Clin Pharmacol 1990; 29: 123–6
Cole AP, Hailey DM. Diazepam and active metabolite in breastmilk and their transfer to the neonate. Arch Dis Child 1975; 50: 741–2
Whitelaw AG, Cummings AJ, McFadyen IR. Effect of maternal lorazepam on the neonate. Br Med J Clin Res Ed 1981; 282: 1106–8
Summerfield RJ, Nielsen MS. Excretion of lorazepam into breast milk. Br J Anaesth 1985; 57: 1042–3
Matheson I, Lunde PK, Bredesen JE. Midazolam and nitrazepam in the maternity ward: milk concentrations and clinical effects. Br J Clin Pharmacol 1990; 30: 787–93
Patrick MJ, Tilstone WJ, Reavey P. Diazepam and breast feeding. Lancet 1972; 1: 542–3
Data on file; Schering Plough, January 18, 1993
Schmidt D, Krämer G. The new anticonvulsant drugs: implications for avoidance of adverse effects. Drug Saf 1994; 11: 422–31
Data on file; Parke Davies, protocol 945–196-0
Tomson T, Öhman I, Vitols S. Lamotrigine in pregnancy and lactation: a case report. Epilepsia 1997; 38: 1039–41
Rambeck B, Kurlemann G, Stodieck SR, et al. Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. Eur J Clin Pharmacol 1997; 51: 481–4
Berry DJ. The disposition of lamotrigine throughout pregnancy [abstract no. 90]. In: Sixth international congress of therapeutic drug monitoring and clinical toxicology: 1999 Sept 13-17: Cairns. Ther Drug Monit, 1999; 21: 478
Öhman I, Tomson T, Vitols S. Lamotrigine (LTG) pharmacokinetics during delivery and lactation [abstract no. 201]. In: Sixth international congress of therapeutic drug monitoring and clinical toxicology: 1999 Sept 13-17: Cairns. Ther Drug Monit 1999; 21: 478
Tran A, O’Mahoney T, Rey E, et al. Vigabatrin: placental transfer in vivo and excretion into breast milk of the enantiomers. Br J Clin Pharmacol 1998; 45: 409–11
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hägg, S., Spigset, O. Anticonvulsant Use During Lactation. Drug-Safety 22, 425–440 (2000). https://doi.org/10.2165/00002018-200022060-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200022060-00002